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A 52-year-old woman and lifetime nonsmoker was pre-sented initially with pleuritic chest pain. Investigations 
revealed a small lower left lobe nodule, extensive intratho-
racic lymphadenopathy, and a large adnexal lesion. Her 
initial brain magnetic resonance imaging was negative. 
Biopsies revealed an adenocarcinoma, TTF-1 positive com-
patible with a primary lung carcinoma. Molecular testing 
was negative for epidermal growth factor receptor muta-
tions, but immunohistochemical staining revealed positiv-
ity for ELM4-ALK fusion, which was confirmed by FISH. 
After failing standard chemotherapy, crizotinib was initi-
ated as second-line therapy with rapid symptomatic and 
radiological response. She remained on crizotinib for 2 
years when she developed a vague and nonspecific feel-
ing of bruising over her right temporal area. She denied 
any other neurological symptoms and was otherwise clini-
cally asymptomatic. Despite the unusual symptoms a brain 
magnetic resonance imaging was ordered. Surprisingly, 
imaging revealed innumerable metastatic foci distributed 
throughout the brain (Fig. 1). The lesions ranged from 5 
to 10 mm with the largest lesion measuring 1.7 cm. Almost 
all the lesions showed evidence of iron deposition indicat-
ing hemorrhagic metastases. Restaging computed tomog-
raphy scans of the chest and abdomen continued to show 
a sustained partial response to crizotinib. The patient 
was referred to radiation oncology where she benefited 
from whole brain radiotherapy and crizotinib therapy was 
continued.
The systemic efficacy of crizotinib in ALK-positive 
patients has been well described.1,2 However, isolated brain 
metastases, as defined as central nervous system (CNS) 
relapse without evidence of extracranial progression, is 
becoming an increasingly common pattern of progres-
sion in this patient population.3,4 Isolated relapse could be 
explained by reduced concentrations of crizotinib in cere-
brospinal fluid suggesting that the CNS represents a sanctu-
ary site.5 This mirrors the situation seen in patients treated 
with epidermal growth factor receptor tyrosine kinase 
inhibitors.6 Interestingly, our patient presented with dif-
fuse hemorrhagic metastases. The incidence of spontaneous 
intracranial hemorrhage in patients with non–small-cell lung 
cancer (NSCLC) with brain metastasis is estimated at 1.2%.7 
There are no published reports of intracranial hemorrhage 
in patients with ALK-positive NSCLC treated with crizo-
tinib. A recent Children’s Oncology Group trial evaluated 
single agent crizotinib in pediatric oncology patients with 
refractory solid tumors.8 Two patients with primary CNS 
tumors developed intratumoral hemorrhages which were 
deemed possibly related to crizotinib. Subsequently, the trial 
was amended to exclude future patients with CNS tumors. 
There are also several reports of patients with NSCLC pre-
senting with intracranial hemorrhage (both subdural and 
intratumoral) while on gefitinib, although it could not be 
confirmed whether bleeding was spontaneous or treatment 
related.9,10 Whereas there is no definitive evidence to suggest 
that patients on tyrosine kinase inhibitors are at higher risk 
of intracranial bleeding, physicians must remain vigilant as 
the use of targeted therapies and incidence of isolated CNS 
relapse increases.
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FIGURE 1. A–D, Diffuse hemor-
rhagic metastatic foci in the brain 
after 2 years of crizotinib therapy. 
The presence of iron deposition 
indicating hemorrhagic nature better 
seen with GRE with gadolinium con-
trast MRI sequences (A, C), than with 
FLAIR sequences (B, D). GRE, gradi-
ent echo; MRI, magnetic resonance 
imaging; FLAIR, fluid-attenuated 
inversion recovery.
